

# Hepcare

## **Hepatitis C** antiviral therapy baseline and failure **Registry** in Europe by ESAR

Charles Boucher  
Erasmus Medical Center  
Erasmus University  
Rotterdam, the Netherlands

---

# Rationale



- Success rate of DAA is very high 90% in trials, anticipated 80% in real life
  - Failure will occur in a small proportion of patients
  - Insight into risk factors for therapy failure relevant to clinical practice is needed
  - Large data sets / multicenter collaboration is required
-

# Design

- International multicenter registry
- Web based submission form



# Inclusion criteria



- Baseline NS3/NS5 sequences prior to DAA therapy or
  - Established failure on a DAA-containing regimen.  
Failure is defined as:
    - Insufficient response/viral rebound during therapy (meeting stopping rules)
    - Viral rebound after therapy
  - Age above 18
-

# Minimal requirements



- Fibrosis stage
  - Antiviral therapy history
  - Viral load response
  - Genotypic resistance test result at failure
-

# Why contribute

- Improve understanding of therapy failure
  - Participation does not affect data ownership( strict governance rules)
  - Participation does not affect possibility to publish your own data
  - Easy submission procedures
  - Become a active member of the ESAR community
-

# How to submit

- Link is available via the ESAR website [www.esar-europe.eu](http://www.esar-europe.eu)
  - For large datasets, data dump is possible
-

# Acknowledgements



- CRP-Santé
    - Jean-Claude Schmit
    - Daniel Struck
  - University of Rome
    - Carlo Perno
  - UMC Utrecht
    - Annemarie Wensing
    - Joop Arends
    - Lucas Hermans
    - Greet Boland
-